#85 Dual Antiplatelet Therapy: 5 Pearls Segme...

MASLD affects nearly one in three adults worldwide, yet many patients remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening? When is a FIB-4 enough, and when should we move to elastography or hepatology referr ...  Show more

What blood pressure should we target in patients on hemodialysis? Why volume control remains the foundation of treatment? How blood pressure targets differ from the general population. Learn practical pearls on medication timing around dialysis, drug dialyzability, antihypertensi ...  Show more

Send us Fan MailNinja Nerds!Welcome to the Ninja Nerd Podcast with Zach and Rob! In this episode, we explore Antiplatelets, Anticoagulants, and Thrombolytics, focusing on their mechanisms and clinical uses. Topics include the pharmacology of antiplatelet agents such as aspirin an ...  Show more

Send us Fan MailThis week, Rob and Zach will be talking about Anticoagulants, Thrombolytics, and Antiplatelet AgentsWe will be discussing the following topics within this episode on Anticoagulants, Thrombolytics, and Antiplatelet Agents!Hemostasis: Coagulation Cascade, Extrinsic ...  Show more

How do you predict which intermediate-risk patients will suddenly deteriorate? What role do risk scores, biomarkers, imaging, and hemodynamics play in decision-making? Should these patients receive anticoagulation alone, or is thrombolysis warranted? When should you consider cath ...  Show more

Every time we admit or care for a critically ill patient, we must consider their risk for deep venous thrombosis, or DVT. Many of our patients are at higher risk for DVT than the general population, but anticoagulants are not wholly benign drugs. What do we do? How do we ...